FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019399383> ?p ?o ?g. }

• W2019399383 endingPage "137" @default.
• W2019399383 startingPage "132" @default.
• W2019399383 abstract "PurposeTo assess long-term visual outcomes and adverse events from a fluocinolone acetonide (FA) sustained drug delivery implant in eyes with chronic macular edema from central retinal vein occlusion (CRVO).DesignProspective interventional case series.ParticipantsA total of 24 eyes of 23 subjects with vision loss associated with chronic macular edema from CRVO.InterventionImplantation of an intravitreal FA sustained drug delivery system.Main Outcome MeasuresThe primary outcome measure was mean Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity letter score at 36 months after implantation. Secondary outcome measures included number of subjects with ≥10-letter improvement in ETDRS letter score, central foveal thickness (CFT), total macular volume, and intraocular pressure (IOP).ResultsAt 1, 2, and 3 years after implantation, mean visual acuity showed gains of 4.5 (P = 0.52), 8.2 (P = 0.07), and 3.4 (P = 0.64) letters, respectively, and 32%, 56%, and 50% of study eyes, respectively, showed at least a 10-letter gain in ETDRS score. At these same time points, mean CFT improved by 247 (44%; P = 0.002), 212 (38%; P < 0.001), and 250 μm (45%; P<0.001), respectively. During the study period, all phakic eyes ultimately underwent cataract extraction, and 5 eyes underwent glaucoma surgery.ConclusionsThe FA drug delivery system provided sustained visual acuity and anatomic benefit in patients with macular edema from CRVO, and it has promise as a therapeutic option for selected patients with this condition. The main complications were cataract and elevated IOP.Financial Disclosure(s)The authors have no proprietary or commercial interest in any of the materials discussed in this article. To assess long-term visual outcomes and adverse events from a fluocinolone acetonide (FA) sustained drug delivery implant in eyes with chronic macular edema from central retinal vein occlusion (CRVO). Prospective interventional case series. A total of 24 eyes of 23 subjects with vision loss associated with chronic macular edema from CRVO. Implantation of an intravitreal FA sustained drug delivery system. The primary outcome measure was mean Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity letter score at 36 months after implantation. Secondary outcome measures included number of subjects with ≥10-letter improvement in ETDRS letter score, central foveal thickness (CFT), total macular volume, and intraocular pressure (IOP). At 1, 2, and 3 years after implantation, mean visual acuity showed gains of 4.5 (P = 0.52), 8.2 (P = 0.07), and 3.4 (P = 0.64) letters, respectively, and 32%, 56%, and 50% of study eyes, respectively, showed at least a 10-letter gain in ETDRS score. At these same time points, mean CFT improved by 247 (44%; P = 0.002), 212 (38%; P < 0.001), and 250 μm (45%; P<0.001), respectively. During the study period, all phakic eyes ultimately underwent cataract extraction, and 5 eyes underwent glaucoma surgery. The FA drug delivery system provided sustained visual acuity and anatomic benefit in patients with macular edema from CRVO, and it has promise as a therapeutic option for selected patients with this condition. The main complications were cataract and elevated IOP." @default.
• W2019399383 created "2016-06-24" @default.
• W2019399383 creator A5030338050 @default.
• W2019399383 creator A5033501630 @default.
• W2019399383 creator A5090864408 @default.
• W2019399383 date "2012-01-01" @default.
• W2019399383 modified "2023-09-28" @default.
• W2019399383 title "Prospective Study of a Fluocinolone Acetonide Implant for Chronic Macular Edema from Central Retinal Vein Occlusion" @default.
• W2019399383 cites W1565146396 @default.
• W2019399383 cites W1565832645 @default.
• W2019399383 cites W1606072215 @default.
• W2019399383 cites W1898187276 @default.
• W2019399383 cites W1994955730 @default.
• W2019399383 cites W1999776870 @default.
• W2019399383 cites W2038924824 @default.
• W2019399383 cites W2043710992 @default.
• W2019399383 cites W2047424583 @default.
• W2019399383 cites W2060359798 @default.
• W2019399383 cites W2061463978 @default.
• W2019399383 cites W2070554206 @default.
• W2019399383 cites W2073004845 @default.
• W2019399383 cites W2075780935 @default.
• W2019399383 cites W2079345221 @default.
• W2019399383 cites W2128701654 @default.
• W2019399383 cites W2151486474 @default.
• W2019399383 doi "https://doi.org/10.1016/j.ophtha.2011.06.019" @default.
• W2019399383 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21924503" @default.
• W2019399383 hasPublicationYear "2012" @default.
• W2019399383 type Work @default.
• W2019399383 sameAs 2019399383 @default.
• W2019399383 citedByCount "42" @default.
• W2019399383 countsByYear W20193993832012 @default.
• W2019399383 countsByYear W20193993832013 @default.
• W2019399383 countsByYear W20193993832014 @default.
• W2019399383 countsByYear W20193993832015 @default.
• W2019399383 countsByYear W20193993832016 @default.
• W2019399383 countsByYear W20193993832017 @default.
• W2019399383 countsByYear W20193993832018 @default.
• W2019399383 countsByYear W20193993832019 @default.
• W2019399383 countsByYear W20193993832020 @default.
• W2019399383 countsByYear W20193993832021 @default.
• W2019399383 countsByYear W20193993832022 @default.
• W2019399383 countsByYear W20193993832023 @default.
• W2019399383 crossrefType "journal-article" @default.
• W2019399383 hasAuthorship W2019399383A5030338050 @default.
• W2019399383 hasAuthorship W2019399383A5033501630 @default.
• W2019399383 hasAuthorship W2019399383A5090864408 @default.
• W2019399383 hasConcept C118487528 @default.
• W2019399383 hasConcept C134018914 @default.
• W2019399383 hasConcept C141071460 @default.
• W2019399383 hasConcept C188816634 @default.
• W2019399383 hasConcept C2777463590 @default.
• W2019399383 hasConcept C2778257484 @default.
• W2019399383 hasConcept C2778527774 @default.
• W2019399383 hasConcept C2778844676 @default.
• W2019399383 hasConcept C2779829184 @default.
• W2019399383 hasConcept C2780347916 @default.
• W2019399383 hasConcept C2781092963 @default.
• W2019399383 hasConcept C555293320 @default.
• W2019399383 hasConcept C71924100 @default.
• W2019399383 hasConceptScore W2019399383C118487528 @default.
• W2019399383 hasConceptScore W2019399383C134018914 @default.
• W2019399383 hasConceptScore W2019399383C141071460 @default.
• W2019399383 hasConceptScore W2019399383C188816634 @default.
• W2019399383 hasConceptScore W2019399383C2777463590 @default.
• W2019399383 hasConceptScore W2019399383C2778257484 @default.
• W2019399383 hasConceptScore W2019399383C2778527774 @default.
• W2019399383 hasConceptScore W2019399383C2778844676 @default.
• W2019399383 hasConceptScore W2019399383C2779829184 @default.
• W2019399383 hasConceptScore W2019399383C2780347916 @default.
• W2019399383 hasConceptScore W2019399383C2781092963 @default.
• W2019399383 hasConceptScore W2019399383C555293320 @default.
• W2019399383 hasConceptScore W2019399383C71924100 @default.
• W2019399383 hasIssue "1" @default.
• W2019399383 hasLocation W20193993831 @default.
• W2019399383 hasLocation W20193993832 @default.
• W2019399383 hasOpenAccess W2019399383 @default.
• W2019399383 hasPrimaryLocation W20193993831 @default.
• W2019399383 hasRelatedWork W1977181510 @default.
• W2019399383 hasRelatedWork W2000573532 @default.
• W2019399383 hasRelatedWork W2027199077 @default.
• W2019399383 hasRelatedWork W2041448642 @default.
• W2019399383 hasRelatedWork W2069287335 @default.
• W2019399383 hasRelatedWork W2294668099 @default.
• W2019399383 hasRelatedWork W2368356977 @default.
• W2019399383 hasRelatedWork W3011249866 @default.
• W2019399383 hasRelatedWork W3169518082 @default.
• W2019399383 hasRelatedWork W4238335834 @default.
• W2019399383 hasVolume "119" @default.
• W2019399383 isParatext "false" @default.
• W2019399383 isRetracted "false" @default.
• W2019399383 magId "2019399383" @default.
• W2019399383 workType "article" @default.